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Neurodevelopmental disorders (NDDs), which include intellectual disability (ID), epilepsy, and autism spectrum disorder, are a heterogeneous group of disorders caused by abnormal development of the central nervous system (CNS). The complexity of CNS development is reflected in the fact that over 700 genes to date have been associated with ID, and very few occur at high prevalence.[@bib1], [@bib2] Because of the extreme genetic heterogeneity of ID, the utilization of next-generation sequencing (NGS) technology provides an efficient method of determining the genetic cause of ID in individuals and discovering ID-associated genes. In addition, NGS of trios enables detection of *de novo* mutations,[@bib3] including single-nucleotide variants (SNVs) and small indels, which are a major contributing factor to the genetic etiology of moderate to severe ID and NDDs.[@bib4], [@bib5], [@bib6], [@bib7]

In this study, we used NGS approaches to identify three *de novo* variants in WAS protein family member 1 (*WASF1* \[MIM: [605035](605035){#intref0010}\]), which encodes WASF1 (also known as WAVE1), in five unrelated individuals with overlapping neurodevelopmental abnormalities, including severe ID with autistic features and seizures. We used Matchmaker Exchange (MME)[@bib8] to connect the four international centers, which had each independently identified *WASF1* as a candidate gene. All three *de novo* variants, including a recurrent truncating variant, cluster within the C-terminal actin-binding WCA domain of WASF1 and are predicted to result in a truncated protein.

The five affected individuals described in this report are from non-consanguineous families and are unrelated. All participants and parents gave informed consent, and the studies were approved by the appropriate institutional research ethics boards (Children's Hospital of Eastern Ontario, Ottawa, Canada; IWK Health Centre, Halifax, Canada; Groupe Hospitalier Pitié-Salpêtrière, Paris, France; East of England Cambridge South, Cambridge, UK; Santa Maria Hospital, Lisbon, Portugal; and Radboud University Medical Center, Nijmegen, the Netherlands \[2011-188\]). The five affected individuals (P1--P5) have moderate to profound ID with autistic features, seizures, severe impairments in speech, gross motor delay, and a paucity of significant congenital abnormalities. A detailed clinical overview is provided in [Table 1](#tbl1){ref-type="table"}. The affected individuals have midfacial hypoplasia but lack a recognizable dysmorphic facial phenotype ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1D). P5 started walking at 25 months, P1 and P2 began walking at age 3--4 years, and P4 did not walk until age 10 years. P1 requires wheelchair assistance when traveling out of his home. P3 has never achieved independent ambulation. All affected individuals either are non-verbal or have limited speech with a few or single words. All affected individuals except P5 have seizures, although these include a range of seizure types, including generalized and focal seizures; all require antiepileptic therapy. Four of the affected individuals (P1, P2, P4 and P5) had significant hypotonia in infancy, and two (P1 and P4) were described as having a wide-based gait, poor balance, and hyperactivity of movements. Musculoskeletal findings included joint hyperflexibility, ankle valgus, and pes planus in the more severely affected individuals. P5 presented with upper-limb dystonia in the first year of life. A high pain tolerance was observed in P1 and P3, whereas P4 and P5 exhibited automutilation, which is observed in those with an abnormal response to pain. Computed tomography of P1 showed mild atrophy near the Sylvian fissures, magnetic resonance imaging (MRI) of P2 and P3 was normal, and MRI of P4 revealed abnormalities of the periventricular white matter, although this individual also suffered a traumatic birth. MRI of P5 showed enlarged ventricles. Toe abnormalities (short third and fourth toes) were noted in three of the four affected individuals ([Figures S1](#mmc1){ref-type="supplementary-material"}E--S1G). Testing for a range of other genetic conditions was undertaken in the affected individuals but resulted in no alternate diagnoses. Specific gene testing included *MECP2*, *ATRX*, *UBE3A*, *CDKL5*, *MEF2C*, *FOXG1*, *TCF4*, and *NRXN1*, reflecting the differential diagnosis and developmental severity of the condition. All had a normal result on diagnostic microarray testing. Metabolic testing was normal, as was a muscle biopsy of P3.Table 1Key Clinical Features of Affected Individuals**DetailP1P2P3P4P5General**Age (years)2123233023Sexmalemalemalefemalemale**Birth**Gestation (weeks)404139NR41Weight (g)3,8004,1003,3704,0204,020Head circumference (cm)NR35.535.5NR35.5**Neurological**Intellectual disabilitysevere to profoundmoderate to severesevereprofoundmoderate to severeSeizuresonset at 8 years; focal with occasional GTConset at 6 years; absence and GTConset at 8 months; infantile spasms initially, now GTConset NR; temporal-lobe epilepsy with partial seizuresnoneSpeechsingle wordssimple sentencesnon-verbalNRsingle wordsHypotoniayesyesnoyes (axial with hypertonia of extremities)yes (head control achieved at 11 months)History of regressionnonoyes (8 months)arrested development at age 1 year, 10 monthsnoWide-based gait with poor balanceyesnonon-ambulantyesyesHigh pain toleranceyesnoyespossible (automutilation)yes (automutilation)Head imagingMRI: scarce periventricular white matter, enlarged ventriclesMRI: normalMRI: normalCT: mild atrophy near Sylvian fissuresMRI: enlarged ventricles**Current Measurements**Head circumference (cm)50.4 (\<P1; −3.2 SD)58 (P98; +2 SD)53.2 (P25; −1.3 SD)54 (P25; −0.3 SD)57 (P99; +2.4 SD)Weight (kg)40.8 (\<P1)82 (P80)40.2 (P25)unknown65 (P70)Height (cm)156.7 (\<P1; −2.8 SD)183 (P80; +1 SD)168 (P10; −1.2 SD)150 (P2; −2.8 SD)175 (P97; +1.8 SD)**Motor Development**Age at unsupported sitting18 months9 months6 months22 monthsNRAge at walking4 years3 yearsnon-ambulant10 years25 months**Craniofacial**Midface hypoplasiayesyesnoyesNREyesdeep set, strabismus, gray scleraexophthalmiastrabismus, gray sclerastrabismus, vision loss, upslanted palpebral fissuresstrabismus**Musculoskleletal**Joint hyperflexibilityyesnonoyesyesAnkle valgusyesnonoyesknee recurvatumLong tapered fingersyesnoyesnoNRFeetnarrow, pes planus, short forth toesshort third toesnormalshort, pes planus, short third toespes planus**Other**Nippleswidely spacednormalwidely spacedinvertedNRCafé au lait maculesyesnoyesnoNRFeeding problemstrouble sucking, reflux, easy chokingnocyclic vomiting resolved at age 16 yearsnofeeding difficulties, refluxGenitourinarynonorenal stones, recurrent UTIssmall kidneys, mildly dilated pyelum, recurrent UTIsNRConstipationyesnoyesyesyesHGVSg variantchr6: g.110422797G\>Achr6: g.110422797G\>Achr6: g.110421847G\>Achr6: g.110422831delinsCCTGGCchr6: g.110422797G\>AHGVSc variantc.1516C\>Tc.1516C\>Tc.1558C\>Tc.1482delinsGCCAGGc.1516C\>THGVSp variantp.Arg506Terp.Arg506Terp.Gln520Terp.Ile494MetfsTer23p.Arg506TerGenotypeheterozygousheterozygousheterozygousheterozygousheterozygousInheritance*de novode novode novode novode novo*[^3]

Because the initial genetic tests were negative, all affected individuals had either exome sequencing or whole-genome sequencing (WGS) performed at their respective centers. Details of the methods used for each affected individual are provided in [Table S1](#mmc1){ref-type="supplementary-material"}. Genomic coordinates throughout this report refer to GRCh37, and coding sequence and protein coordinates refer to the canonical transcript (Ensembl: ENST00000392589; GenBank: [NM_003931.2](ncbi-n:NM_003931.2){#intref0015}).

Trio exome sequencing was performed on individual P1 and his parents as part of the Care4Rare Canada research program according to our standard approach as previously described.[@bib9] After filtering for rare variants (with a frequency less than 0.1% in gnomAD and present fewer than six times in our in-house controls), all variants in known disease-related genes were assessed, but no variants that could explain this individual's phenotype were identified. In the search for potential novel genes, possible bi-allelic or X-linked recessive variants were examined, but there were no rare homozygous or hemizygous variants. Compound-heterozygous variants were identified in *CROCC* (MIM: [615776](615776){#intref0020}), but this gene was ruled out as a likely candidate because it has many loss-of-function variants in control databases ([Table S2](#mmc1){ref-type="supplementary-material"}). Finally, *de novo* variants in *WASF1*, *ATP5J* (MIM: [603152](603152){#intref0025}), *SLC38A4* (MIM: [608065](608065){#intref0030}), and *ZNF175* (MIM: [601139](601139){#intref0035}) were identified ([Table S2](#mmc1){ref-type="supplementary-material"}). Assessment of protein localization patterns and function and *in silico* mutation predictions determined that *ATP5J*, *SLC38A4*, and *ZNF175* were unlikely to be responsible for this condition (refer to [Table S2](#mmc1){ref-type="supplementary-material"} for further details). Given the role of WASF1 in actin polymerization and the importance of actin regulation in achieving synaptic plasticity, the *de novo* heterozygous variant in *WASF1* (c.1516C\>T \[p.Arg506Ter\]) was judged to be the strongest candidate for causing this individual's condition and was entered into MME.

Individuals P2 and P5 underwent trio exome sequencing as part of routine diagnostic testing at the Département de Génétique of Hôpital Pitié-Salpêtrière (Paris, France). After filtering for rare variants (with a frequency less than 0.1% in the ExAC Browser), no pathogenic variants, likely pathogenic variants, or variants of unknown significance (VUSs) were identified in known developmental-disease-associated genes. Next, rare variants in genes not previously known to be associated with disease were considered. A heterozygous *de novo* stop-gain variant in *WASF1* (c.1516C\>T \[p.Arg506Ter\]), the same variant identified in P1, was identified in both P2 and P5. A *de novo* missense variant in *CDCA7L* (MIM: [609685](609685){#intref0040}) was also identified in P2 but was not considered likely to be pathogenic ([Table S2](#mmc1){ref-type="supplementary-material"}). No additional variants that required consideration of pathogenicity were identified in P5.

Individual P3 and his mother underwent WGS as part of the National Institute for Health Research (NIHR) BioResource study (UK) as previously described.[@bib10] No pathogenic or likely pathogenic variants were found in known developmental-disease-associated genes, but a heterozygous stop-gain variant in *WASF1* (c.1558C\>T \[p.Gln520Ter\]), which was not present in the unaffected mother, was identified. Sanger sequencing of P3 and his parents confirmed that the variant occurs *de novo* in the affected individual ([Figure S2](#mmc1){ref-type="supplementary-material"}B). A hemizygous missense variant in X-linked *ACSL4* (MIM: [300157](300157){#intref0045}), in which variants can cause X-linked ID (MIM: [300387](300387){#intref0050}), was also identified in P3 and was heterozygous in the mother. This was classified as a VUS because the variant was not previously associated with disease ([Table S2](#mmc1){ref-type="supplementary-material"}).

Individual P4 underwent trio exome sequencing as part of routine diagnostic testing (Groningen, the Netherlands). No pathogenic variants, likely pathogenic variants, or VUSs in known developmental-disease-associated genes were identified. Next, *de novo* variants in genes not previously known to be associated with disease were considered. A heterozygous *de novo* frameshift variant in *WASF1* (c.1482delinsGCCAGG \[p.Ile494MetfsTer23\]) was identified. No other coding variants that occurred *de novo* were identified.

Initially, the four groups independently identified *WASF1* as a strong candidate because of features consistent with those of developmental-disorder-associated genes. This gene is constrained for loss-of-function variation in the ExAC Browser (pLi = 0.91)[@bib11] and is highly and specifically expressed in the adult human brain.[@bib12] All three *WASF1* variants are absent from 1000 Genomes, the ExAC Browser, and gnomAD.[@bib11], [@bib13] The variants in individuals P1 and P3--P5 were confirmed to be *de novo* by Sanger sequencing of the trio ([Figure S2](#mmc1){ref-type="supplementary-material"}B). The read depths for P2 and his mother and father were 127 (with 69 read counts for the alternate allele), 143, and 124, respectively. MME connected three of the groups, and the fourth was connected by personal correspondence with the UK group.

Interestingly, the three *de novo* variants appear to cluster around the WASP-homology 2 (WH2) domain of WASF1 ([Figure 1](#fig1){ref-type="fig"}A). A previously published method was used to determine that the clustering is statistically significant (p = 1.31 × 10^−6^).[@bib15] The C-terminal actin-binding WCA region, which includes the WH2 domain, is highly conserved throughout evolution ([Figure 1](#fig1){ref-type="fig"}B). The WCA region plays an important role in regulating WASF1[@bib16], [@bib17] so that actin and the Arp2/3 complex can bind to the WCA domain to promote actin polymerization.[@bib18] All three variants identified in the affected individuals fall either within the last 50 bp of the penultimate exon or within the last exon ([Figure 1](#fig1){ref-type="fig"}C) and are therefore predicted to result in the generation of a truncated protein that partially or fully eliminates this WCA domain.[@bib19]Figure 1Schematic Diagrams Showing Structure of WASF1 and *WASF1*(A) Schematic diagram showing full-length WASF1 (also known as WAVE1 \[Ensembl: ENSP00000376368\]). Variants in the five individuals (indicated in red) cluster around the WH2 domain (domain coordinates are from Stradal et al.[@bib14]). P1, P2, and P5 have p.Arg506Ter, P3 has p.Gln520Ter, and P4 has p.Ile494MetfsTer23. Abbreviations are as follows: WH1, WASP homology 1 domain; B, basic domain; Pro, proline-rich region; WH2, WASP homology 2 domain (also known as the verprolin homology domain); C, cofilin homology domain; A, acidic domain; WCA, collective name for the WH2, C, and A domains.(B) Schematic diagram showing the amino acid sequence of part of WASF1. The WCA region of WASF1 is conserved throughout evolution. Yellow highlights residues that differ from the human protein sequence.(C) Schematic diagram showing the 3′ part of *WASF1*, including locations of the participants' variants in red. The gray boxes represent the coding sequence, and the white box represents the 3′ UTR. The variant in P1, P2, and P5 is 6 bps from the end of exon 9 (the penultimate exon). The variant in P4 is 40 bps from the end of exon 9. The variant in P3 is within exon 10 (the final exon).

Next, the potential effect of the identified *WASF1* variants on protein function was determined. Primary fibroblasts were obtained from individuals P1 and P2, who carry the same c.1516C\>T variant (predicted to introduce a premature stop codon at amino acid 506). Amounts of *WASF1* mRNA and WASF1 were examined. Real-time PCR showed variable levels of mRNA between the two affected individuals and control individuals ([Figure 2](#fig2){ref-type="fig"}A). For western blot analysis of WASF1, total protein extracts were probed with either a C-terminal antibody (epitope located after amino acid 506; Abcam, ab50356) or an N-terminal antibody (Sigma-Aldrich, W0267) against WASF1. Comparison of control and affected individuals revealed that the cells from affected individuals had both the full-length WASF1 (75 kDa) and a truncated ∼70 kDa protein that was not observed in control cells ([Figures 2](#fig2){ref-type="fig"}B and 2C). Densitometry quantification of these bands showed that the full-length protein was present at approximately 50% of the control levels, reflecting the presence of one wild-type allele, whereas the truncated protein was present at 14%--25% of control levels ([Figures 2](#fig2){ref-type="fig"}B and 2C). This suggests that although a truncated isoform is produced, it is unstable at either the mRNA or protein level such that the amount of protein is reduced. Therefore, the *WASF1* c.1516C\>T variant causes the production of a shorter mutant protein rather than the absence of a protein due to complete nonsense-mediated decay of the primary transcript.Figure 2Amounts of *WASF1* mRNA and WASF1 in Fibroblasts Derived from Affected Individuals with the c.1516C\>T Variant(A) RT-qPCR shows variable amounts of *WASF1* mRNA between primary fibroblasts derived from individuals P1 and P2 and healthy control fibroblasts.(B) Western blot analysis using an antibody with an epitope downstream of Arg506 showed that the amount of full-length WASF1 was approximately 50% lower in affected fibroblasts than in control fibroblasts.(C) Western blot analysis using an antibody with an epitope in the N-terminal region of WASF1 showed the presence of the full-length and truncated WASF1 in affected fibroblasts. The truncated WASF1 was not present in control fibroblasts. All experiments were performed with fibroblasts derived from three healthy control individuals. Western blots were performed in triplicate, and band intensity was quantified with Image Lab Software (Bio-Rad).Error bars indicate the range of measurement of triplicate samples.

WASF1 plays a critical role in binding actin to initiate actin polymerization. Examination of the reorganization of the actin cytoskeleton during lamellipodia formation in fibroblasts was used for testing this role.[@bib20], [@bib21], [@bib22] Serum-starved fibroblasts were trypsinized, re-plated onto poly-[l]{.smallcaps}-lysine-coated coverslips, and stimulated with platelet-derived growth factor (PDGF; Sigma-Aldrich, P3201) for inducing the formation of lamellipodia, as previously described.[@bib20] Then cells were fixed, filamentous actin was visualized by labeling with phalloidin (Thermo Fisher Scientific, A12349), and the actin phenotype was quantified in each genotype. In the majority of control cells (77%), actin at the cell periphery formed well-organized, sheet-like lamellipodia structures ([Figures 3](#fig3){ref-type="fig"}A and 3B, white arrowhead; [Figure S3](#mmc1){ref-type="supplementary-material"}). This was interspersed with cells in which the actin sheets were interjected by filopodia, which are finger-like actin projections ([Figures 3](#fig3){ref-type="fig"}A and 3B, red asterisk; [Figure S3](#mmc1){ref-type="supplementary-material"}). We next assessed fibroblasts from affected individuals and found that although a sheet-like lamellipodia structure was observed along the periphery of 34% and 24% of P1 and P2 cells, respectively, the actin bundles were thinner and less organized than in the control cells ([Figures 3](#fig3){ref-type="fig"}A and 3B). We also noted that a portion of cells from P1 and P2 had severe disruptions in actin organization such that no lamellipodia delineated the cell periphery and only filopodial projections were present (12% and 11% for P1 and P2, respectively; [Figures 3](#fig3){ref-type="fig"}A and 3B). This phenotype was not seen in control cells. Therefore, cells from affected individuals have an alteration in actin organization, suggesting that the presence of a truncated WASF1 results in defective actin remodeling during the formation of lamellipodia.Figure 3Lamellipodia Formation and Mitochondrial Morphology in Fibroblasts Derived from Individuals with the c.1516C\>T Variant(A) Primary fibroblasts were treated with PDGF for inducing the formation of lamellipodia. Visualization of the filamentous actin by phalloidin staining revealed the disruption of actin in the cell periphery of P1 and P2 fibroblasts. In the insets, lamellipodia and filopodia are marked by white arrowheads and red asterisks, respectively. Scale bars represent 10 μm.(B) Cells were categorized into three groups on the basis of the predominant actin phenotype present: cells displaying lamellipodia only, cells displaying a mixture of lamellipodia and filopodia, and cells displaying filopodia only. Quantification based on these three categories indicates that significantly fewer affected fibroblasts than control fibroblasts are able to form solely lamellipodia.(C) Confocal microscopic analysis of TOMM-20-immunostained mitochondria (in green) indicated that both affected fibroblasts have significantly elongated mitochondria. The nuclei were visualized by DAPI staining (in blue).

Finally, WASF1-dependent actin polymerization has been shown to mediate mitochondrial trafficking into dendritic spines in primary neurons;[@bib23] therefore, we assessed mitochondrial morphology in fibroblasts with the c.1516C\>T variant. Mitochondria were visualized and the average length was quantified as previously described.[@bib24] As expected, a dense and complex network of mitochondria was present in both control and affected fibroblasts. Quantification revealed that mitochondria in the cells from affected individuals were significantly longer than those in control fibroblasts ([Figure 3](#fig3){ref-type="fig"}C). This result suggests that the presence of the c.1516C\>T variant in *WASF1* disrupts the regulation of mitochondrial dynamics and alters the normal balance between fission and fusion in affected fibroblasts.

This report provides evidence that *de novo* truncating variants in *WASF1* in five unrelated individuals cause a NDD comprising severe ID with autistic features, seizures, and developmental delay. Interestingly, three of the five individuals in this study have the same *de novo* variant (c.1516C\>T \[Ensembl: ENST00000392589\]). Three of the four individuals have VUSs in other genes in addition to the *WASF1* variants. Population-level sequencing initiatives have enabled increased recognition of the prevalence of recurrent benign *de novo* mutations.[@bib25] Although it is unlikely, the possibility that they contribute to the respective individuals' phenotypes cannot be excluded.

The variants described as associated with this NDD are all stop-gain or frameshift variants and significantly cluster around the C-terminal WH2 domain in the WCA region of WASF1. The truncated protein observed for c.1516C\>T (p.Arg506Ter) suggests that all three variants are likely to lead to altered function of the mutant protein rather than complete protein loss or haploinsufficiency from degradation through nonsense-mediated decay. In a disease context, recurrent *de novo* events are known to be associated with specific dominant-negative or gain-of-function effects, such as *FGFR3* (MIM: [134934](134934){#intref0055}) variants causing achondroplasia (MIM: [100800](100800){#intref0060}), and are usually missense variants.[@bib26] Clustering and recurrence of *de novo* protein-truncating mutations also do occur, albeit less frequently because the genic localization of a pathogenic mutation resulting in haploinsufficiency is generally not critical.[@bib15], [@bib27], [@bib28] Additional individuals with rare *WASF1* variants are required for determining whether any pathogenic variants lie outside of this WCA region and/or whether a spectrum of phenotypes is perhaps associated with different variants in this gene.

WASF1 is an essential component of the actin pathway where RAC1 activation triggers a conformational change in WASF1 to allow binding of actin and ARP2/3 to the WCA domain to initiate actin polymerization.[@bib20], [@bib21], [@bib29], [@bib30] The presence of a truncated protein that lacks the WCA region, as observed here, most likely disrupts the WASF1 complex itself, its interactions with CYFIP1, its proteasomal degradation, and the binding of actin ([Figure 2](#fig2){ref-type="fig"}C).[@bib16], [@bib17], [@bib31] Like mutations in *WASF1*, mutations in *RAC1* similarly disrupt the formation of lamellipodia in fibroblasts,[@bib32] indicating that the organization and stabilization of actin bundles during the formation of lamellipodia is likely to be compromised by truncated WASF1.

WASF1-dependent actin polymerization is known to be important in CNS development and synaptic plasticity.[@bib18], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39] Two different *WASF1*-null mouse models demonstrate cognitive impairments, including deficits in sensorimotor function, learning, and memory.[@bib12], [@bib40] In addition, mutations in a number of genes in the actin regulatory pathway, namely, formin 2 (*FMN2* \[MIM: [606373](606373){#intref0065}\]),[@bib41] actin gamma-1 (*ACTG1* \[MIM: [102560](102560){#intref0070}\]),[@bib42] rho guanine nucleotide exchange factor 6 (*ARHGEF6* \[MIM: [300267](300267){#intref0075}\]),[@bib43], [@bib44] and RAS-related C3 botulinum toxin substrate 1 (*RAC1* \[MIM: [602048](602048){#intref0080}\]),[@bib32] are associated with ID.

WASF1 localizes to the outer mitochondrial membrane, where it has been shown to play a role in the trafficking of mitochondria to the dendritic spines.[@bib23], [@bib44], [@bib45] Actin itself has also been shown to be necessary for mediating mitochondrial fission.[@bib45] Given that fibroblasts derived from affected individuals with the c.1516C\>T variant show elongated mitochondria ([Figure 3](#fig3){ref-type="fig"}C), WASF1 most likely plays additional roles in regulating mitochondrial dynamics, although how variants in *WASF1* affect mitochondrial function in affected individuals remains to be elucidated.

In summary, *de novo* heterozygous truncating variants in *WASF1* cause a NDD in individuals with ID associated with autistic features, seizures, and developmental delay. The three *de novo* variants, identified in five unrelated affected individuals, are all predicted to affect the actin-binding C-terminal WCA region of WASF1. The clustering of truncating pathogenic variants reported here and the presence of a truncated protein in cells from affected individuals imply either a gain-of-function or dominant-negative mechanism of disease. Because WASF1 functions within a large protein complex with ABI2, CYFIP1 or CYFIP2, BRK1, and NCKAP1, the hypothesis that these variants have a most likely dominant-negative effect remains to be tested. This study further expands the list of actin-regulatory-pathway genes associated with NDD and demonstrates the value of sharing genomic data through MME to identify the consequence of extremely rare mutational events.
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